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Abstract
Objectives—Nonalcoholic fatty liver disease (NAFLD) ranges from simple steatosis to hepatic
inflammation to cirrhosis. We sought to identify common genetic variants contributing to
NAFLD, using CT measured fatty liver (FL), and alanine aminotransferase levels (ALT), as a
biochemical marker of hepatic inflammation.
Methods—We employed a correlated meta-analysis (CMA) to test whether combining FL and
ALT genomewide association (GWA) results, using ~2.5 million imputed SNPs, could enhance
ability to detect variants influencing both traits.
Results—Variants of the ERLIN1-CHUK-CWF19L1 gene cluster were associated with
concomitant variation of FL and ALT. Nine variants (rs2862954, rs1408579, rs10883451,
rs11597086, rs11591741, rs17729876, rs17668255, rs17668357, rs12784396) displayed
genomewide significant associations at loci concomitantly influencing FL and ALT
(2.47×10−9≤CMA-p≤4.29×10−10) as compared with the suggestive significance of marginal tests
(4.11×10−5≤GWA-p≤2.34×10−6). For example, the missense variant in ERLIN1-rs2862954 was
genomewide significant (CMA-p=4.88×10−10) for the combination of FL and ALT, while the
respective univariate associations were suggestive (FL:p=5.74×10−6, ALT:p=3.71×10−6). Further
we investigated whether the concomitant associations were driven mainly by ALT levels. When
we adjusted FL by ALT, the correlated associations diminished but did not vanish (CMA-
p≤3.3×10−7). Our findings suggest ERLIN1-CHUK-CWF19L1 variants are associated with early
stage of FL accumulation (measured by CT) to hepatic inflammation (ALT levels), and the
association enhances when accounting for the correlations between their scans.
Conclusions—CMA approach enhanced the ability to identify novel variants of the ERLIN1-
CHUK-CWF19L1 influencing both simple steatosis and hepatic steatosis with inflammation,
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which suggest that this gene cluster may regulate the susceptibility of NAFLD in a wide spectrum
of disease.
1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is an emerging metabolic-related disorder
characterized by hepatic fat accumulation, predominantly in the form of triglycerides (TG),
in the absence of significant ethanol consumption or other known causes of liver disease [1,
2]. NAFLD is a common disease and ranges from simple steatosis, which is associated with
metabolic abnormalities, to nonalcoholic steatohepatitis (NASH), which presents as
inflammatory damage in the liver and can progress ultimately to cirrhosis and liver cancer
[1].
Computed tomography (CT) imaging of the liver is a non-invasive procedure which allows
for an accurate and reliable assessment of fat content in the hepatic parenchyma. There is an
inverse relationship between liver fat burden and liver attenuation, and it has a sensitivity of
82% and 100% specificity for detecting >30% steatosis [3, 4]. Alanine transaminase (ALT)
is a liver-derived enzyme, and elevated serum levels of ALT are associated with liver
damage. ALT has been used as a biochemical marker of hepatic inflammation to monitor the
course and severity of NAFLD [5, 6], although it is a non-specific marker of liver damage.
The heritabilities of these traits have been estimated as 25% – 30% for CT measured fatty
liver (FL [7]), and 33% – 55% for serum ALT levels [8, 9]. To date, a limited number of
genes has demonstrated associations with susceptibility to FL, including PNPLA3, NCAN,
PPP1R3B, GCKR, and LYPLAL1, and explain less than 5% of the proportion of variance in
FL [7, 10–13]. Also, association of CPN1-ERLIN1-CHUK with ALT levels was reported
[8]. There is a significant correlation between these traits of NAFLD. The correlation
between FL an ALT was reported as 0.405 [14], suggesting common genetic effect.
Simultaneous consideration of FL and ALT could enhance the identification of etiologic
factors, especially genes. The goal of this study was to search for genetic variants that
account for some of the correlated architecture between CT measured FL and levels of ALT
by combining the genomewide association scans for these phenotypes in a correlated meta-
analysis (CMA) using 2,705 European American participants of the NHLBI Family Heart
Study (FamHS).
2. Material and Methods
2.1. Study Design and Sample
The FamHS (https://dsgweb.wustl.edu/fhscc/) recruited 1,200 families, half randomly
sampled, and half selected because of an excess of coronary heart disease or related-risk
factor abnormalities as compared with age- and sex-specific population rates [15] from four
population-based parent studies: the Framingham Heart Study, the Utah Family Tree Study,
and two centers for the Atherosclerosis Risk in Communities study (Minneapolis, and
Forsyth County, NC). Study participants belonging to the largest pedigrees were invited to
undergo CT imaging for assessment of coronary artery calcification; these scans also were
used to quantitate hepatic and abdominal fat burden. A total of 2,767 Caucasian subjects in
510 extended families were examined.
2.2. Phenotypes
Participants underwent a cardiac multidetector CT exam with four detectors using a
standardized protocol as described previously [16]. In brief, two cardiac gated images of the
thorax included the upper third of the liver. The unenhanced CT images were reviewed on a
GE Advantage Windows Workstation (General Electric Healthcare, Waukesha, WI). Liver
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attenuation (LA) was measured by placing three round regions of interest (ROI’s) in two
slices of the superior right lobe of the liver. The six ROI’s values (three from each slice)
were then averaged as a mean LA. All participants were imaged with standardized phantom
that contains material that simulates water (HU=0) as well as increasing densities of calcium
(50, 100 and 200 mg of calcium). The phantom measures at water density were used to
adjust and standardize LA measurements. Lower LA values indicate higher fat content. We
inverted the scale of LA by multiplying each value by negative one to produce a phenotype
of fatty liver (FL) for which higher values are associated with greater liver fat. ALT (in units
of U/L) was measured by reaction rate assay based on the conversion of NADH to NAD
using the Vitros analyzer (Johnson & Johnson Clinical Diagnostics, Inc. Rochester NY
14650).
Subjects were excluded from the analyses if they were: (i) heavy drinkers (men: >21 drinks/
week and women: >14 drink drinks/week) or (ii) taking Amiodarone, or (iii) positive for
hepatitis C antibodies for ALT analysis (88 subjects for FL and 124 subjects for ALT
excluded). Alcohol intake was assessed during interview. The subjects reported whether he/
she “presently drinks alcoholic beverage at all (alcohol intake: 0 = No, 1 =Yes)” and if so,
the number of 1.5 oz cocktails, 12 oz glasses (or can) of beer, and 4 oz glasses of wine they
consumed per day in 1 week. Total number of alcohol intake in grams per day was
calculated from the reported intakes of beer, wine, and spirits. Medications were assessed at
the clinic visit in which subjects brought all medications they were taking. Amiodarone has
the effect of increasing liver density, and thus we excluded subjects taking this medication.
Finally, information of hepatitis C antibodies was obtained from questionnaire.
2.3. Genotypes
A total of 2,705 subjects for the analysis were typed on three Illumina platforms: (i) 974
subjects with 547,353 SNP markers on the Illumina HumMap 550K chip, (ii) 249 subjects
with 576,888 SNP markers on the Human 610-Quadv1 Illumina chip, and (iii) 1,482
subjects with 1,111,639 SNP markers on the Human 1M-Duov3 Illumina chip [18]. Quality
control was performed before imputation by checking pedigree relationships (using GRR
software), and excluding SNPs with low call rates (< 98%). A framework map for
imputation was defined by choosing SNPs on all platforms, and restricting to those with
minor allele frequency between 1% and 50%, and excluding SNPs with significant (p< 1.0 ×
10−6) departure from Hardy-Weinberg equilibrium. This panel was used to impute ~ 2.5 M
SNPs based on phased haplotypes from HapMap (release 22, build 36, CEU, http://
hapmap.ncbi.nlm.nih.gov/downloads/phasing/2007-08_rel22/phased/) using MACH
(version 1.0.16, http://www.sph.umich.edu/csg/abecasis/mach/). The final data for the GWA
analysis included 2,584 participants for ALT levels and 2,597 participants for CT measured
FL.
2.4. Statistical Analysis
2.4.1. Covariate adjustment—Principal components (PC [19]) were estimated using the
genotypes of the largest sample of independent subjects (N= 753) and then calculated for
family members. The phenotypes were adjusted using two steps: (1) forcing field centers
and genotype chip effects into the regression analysis, and then (2) adding age, age2, sex,
current alcohol intake (Yes/No), phantom, and ten PC using stepwise regression analysis
and retaining terms significant at the 5% level. The residuals were standardized to a mean of
0 and variance of 1 (FL and ALT). Finally, an inverse normal rank transformed within sex
was performed for FL. In the second adjustment for FL, ALT was forced in the covariate list
(in step 1); while FL was forced in the covariate list for ALT (in step 1), similarly to the first
adjustment procedure.
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2.4.2. Heritability estimates—The heritabilities were calculated using a variance
components model as implemented in the computer program SOLAR (http://txbiomed.org/
departments/genetics/genetics-detail?P=37).
2.4.3. Association analysis—GWA analysis was first carried out for each of ALT and
FL assuming additive effects with mixed model linear regression, accounting for
dependency among family members as a function of their kinship correlations (R kinship
package: http://cran.r-project.org/web/packages/GWAF/). Results were filtered to include
SNPs with acceptable imputation quality (r2hat > 0.3) and with effect allele frequency
between 1–99%. To test whether individual variants influence both FL and ALT, we
employed a novel correlated meta-analysis (CMA) approach [20], which combines the SNP-
wise Z-scores corresponding to the p-values, while accounting for the correlation between
scans. In brief, the standard meta-analysis assumes all component scans are independent;
however, correlations among scans can arise for a number of reasons, here, mainly because
the same set of subjects was used for both phenotypes and subjects’ phenotypes are
correlated. Province and Borecki [20, 21] developed a method to empirically estimate the
covariance among scans to be included in a meta-analysis, and to correct the signal inference
in the combined meta p-value. Briefly, all p-values are first converted to corresponding z-
scores, which are assumed to follow a multivariate normal distribution. Since the vast
majority of SNPs in a genome scan is under the null for any given phenotype, the global
degree of correlation between the scans can be calculated to assess the degree of non-
independence. A tetrachoric correlation estimator is used on p-values dichotomized as
(P≤0.5; P>0.5) to minimize the effect of the few SNPs that might be under the alternative.
The estimated correlation is used to adjust the variance estimate of the combined Z-scores.
2.4.3. Regional plot—It was generated with LocusZoom [22], and Haploview (http://
haploview.software.informer.com/) was used for investigation of linkage disequilibrium
(LD) and block structure using the HapMap CEU data.
3. Results
3.1. Characteristics of the Study Sample
Table 1 shows the characteristics of the FamHS participants included in the analysis, in
which 56% of subjects were women. The average age was 57 years, and average body mass
index (BMI) was 28.9 kg/m2. The proportion of subjects with severe obesity (BMI ≥ 35.0
(kg/m2) was 12.5% and with diabetes was 13.4%. The mean levels of TG (144.1 ± 93.9 mg/
dL), ALT (21.7 ± 15.8 U/L [6]) and LA (59.1 ± 11.2 HU [3]) were within normal range
values. The phenotypic correlation between FL and ALT levels was 0.27 (p<0.0001). The
heritability estimates were significant (p < 0.0001) for the covariate-adjusted phenotypes, FL
(0.27±0.04) and ALT (0.26±0.04), suggesting that genetic factors influence the variability
levels of these traits and a search for significant genetic variants is warranted.
3.2. Genomewide association analyses
Univariate GWA analysis revealed associated variants near or in PNPLA3 and PPP1R3B at
genomewide significance levels (p < 5.0 × 10−8, Supplemental Table 1) in FamHS. The
highest association was with a missense locus in PNPLA3 (rs738409: β = 0.34 for the G
allele, P = 2.09 × 10−23), which was previously reported [7] and also detected for magnetic
resonance assessed steatosis [10]. The rs2126259 near-PPP1R3B associated with FL (β =
−0.26 for the A allele, P = 3.28 × 10−8) is in complete linkage disequilibrium (LD) with
rs4240624 (LD=1, r2 =0.80, P = 4.76 × 10−8), which was also previously reported associated
with FL [7]. No loci were associated with ALT levels at genomewide significance level.
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To identify additional variants influencing both FL and ALT, we carried out a correlated
meta-analysis of the two individual scans. Largely, the FL and ALT scans provided
independent information (r=0.045 between the scan p-values). This approach yielded
evidence for association on 10q24–q25 with variants in ERLIN1-CHUK-CWF19L1
(endoplasmic reticulum (ER) lipid raft associated 1; conserved helix-loop-helix ubiquitous
kinase; CWF19-like 1 cell cycle control; and biogenesis of lysosomal organelles complex-1
subunit 2, respectively) gene cluster. The regional plot depicts correlated meta-analysis
associations between variants in ERLIN1-CHUK-CWF19L1 gene cluster with FL and ALT
(Figure 1). Nine SNPs located in two haplotype blocks (HB-1: rs2862954, rs1408579 and
rs10883451 in ERLIN1; and HB-2: rs11597086 and rs11591741 in CHUK, and rs17729876,
rs17668255, rs17668357 and rs12784396 in CWF19L1, Supplementary Figure 1) were
strongly associated with concomitant variation in FL and ALT levels (4.29×10−10 ≤ CMA-p
≤ 1.84×10−9). For example, the correlated meta-analysis showed evidence of a novel
association between the missense-ERLIN1-rs2862954 substitution C>T with decreasing
levels of both FL (β = −0.13±0.03, C allele frequency=0.48) and ALT (β = −0.14±0.03,
Table 2). This finding suggests that the missense-ERLIN1-rs2862954 may regulate the
susceptibility of NAFLD in a broad spectrum of disease. Thus, the correlated meta-analysis
approach enhanced the ability to detect association at genomewide significance level as
compared with suggestive individual scans (2.71×10−6 ≤ GWA-p ≤ 2.75×10−5 for FL or
ALT, Table 2). In addition to these nine SNPs, nineteen SNPs within CHUK-CWF19L1 or
near-ERLIN1 genes showed suggestive associations with concomitant variation of FL and
ALT levels (CMA-p <1.0×10−6, Supplementary Table 2, Supplementary Figure 1).
Since diabetic status and severe obesity are metabolic-related disorders with NAFLD and
may represent potential confounders with NAFLD, we tested the robustness of these
associations while restricting the analysis to subgroups of subjects free of diabetes and/or
severe obesity (BMI ≥ 35.0 kg/m2). Even though the sample sizes were reduced ~23% after
excluding diabetics and severe obese (ALT: 2,597 vs. 2,008 subjects and CT measured FL:
2,584 vs. 1,995 subjects), the association results for CMA and univariate analyses remained
similar (Supplementary Table 3A). Also, the results were similar in non-diabetics
(Supplementary Table 3B) and in non-extreme obese subjects (Supplementary Table 3C).
These findings show evidence that variants within ERLIN1-CHUK-CWF19L1 gene cluster
have concomitant effects on NAFLD traits, even after accounting for some components
related to metabolic syndrome (e.g., diabetes and severe obesity).
To test if the correlated associations of ERLIN1-CHUK-CWF19L1 variants with NAFLD
traits were predominantly due to ALT levels, we adjusted LA by ALT (in addition to the
other covariates, LA_ALT) and carried out correlated meta-analysis between ALT and
FL_ALT. The genomewide significance levels of the correlated meta-analysis were slightly
attenuated (CMA-p < 3.3×10−7, Supplementary Table 4A). We also found similar pattern of
correlated meta-analysis associations when we used the adjusted ALT by FL (ALT_FL) and
FL (CMA-p < 3.7×10−8, Supplementary Table 4B). These findings suggest that variants of
ERLIN1-CHUK-CWF19L1 gene cluster influence both NAFLD traits (FL and ALT), and
the significance of association enhances when accounting for the correlation between their
scans.
4. Discussion
Variants of the ERLIN1-CHUK-CWF19L1 gene cluster associated with both FL and ALT
levels were identified by correlated meta-analysis. Among the nine SNPs at genomewide
significance levels, three of them were in one ERLIN1 haplotype block (rs2862954,
rs1408579 and rs10883451), which includes the missense-ERLIN1-rs2862954 associated
with lower levels of FL and ALT. The other six SNPs were in a single haplotype block that
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spans CHUK (rs11597086 and rs11591741) and CWF19L1 (rs17729876, rs17668255,
rs17668357 and rs12784396). In addition, our findings show that these common variants
may influence both FL and ALT levels, even after accounting for some components related
to metabolic syndrome, such as extreme obesity and diabetes.
Association of missense-ERLIN1-rs2862954 (p= 9.24×10−8 [8]) was previously reported
with ALT levels in a genomewide meta-analysis study including 12,419 European white
subjects (the CoLaus Study from Lausanne Switzerland, the InCHIANTI Study from
Tuscany Italy, and the LOLIPOP Study from London UK). ALT levels have been used as a
biochemical marker of hepatic inflammation [5, 6]; however it is a non-specific marker of
liver damage. Our study shows for the first time that missense-ERLIN1-rs2862954 is
relevant for the early stage of FL accumulation, even before liver damage occurs. ERLIN1
encodes a member of the prohibitin family of proteins that define lipid-raft-like domains of
the endoplasmic reticulum [23]. Lipid rafts are regions of membranes with a distinct,
characteristic structural composition and that appear to act as platforms to colocalize
proteins involved in intracellular signaling pathways [24]. ERLIN1 is expressed in the liver,
among other tissues [25].
Variants of CHUK were also previously reported associated with ALT levels (rs11591741:
p= 2.97×10−8 and rs11597086: p= 1.83×10−8 [8]), and NASH fibrosis (rs11591741:
p=0.010 [13]) in a multivariate model that accounted for sex, BMI, diabetes, alcohol
consumption and PNPLA3 variant (rs738409). The 894 adult patients from the NASH
Clinical Research Network and National Institutes of Health Clinical Center studies were
predominantly Caucasian (85.7%) and 59.4% had definite histological diagnosis for NASH
[13]. CHUK-intronic-rs11591741 is in complete LD with the 5′utr-CWF19L1-rs12784396
(LD=1 and r2=1). These findings suggest a regulatory effect on transcription of CHUK-
CWF19L1 that may influence the development and severity of NAFLD. The CHUK gene
encodes a protein that is an inhibitor of the essential transcription nuclear factor-kappa-beta
(NF-κB) complex via ubiquination pathway, and is involved in inflammatory responses
triggered by cytokines [6]. It is worth pointing out that NF-B activated by IKK-B (IκB
kinase) is implicated in transcription of proinflammatory mediators (e.g., interleukin-1
(IL-1), interleukin-6 (IL-6) and TNF-α). NF-B dependent inflammatory mediators produced
in hepatocytes down-regulate insulin sensitivity and trigger liver injury [26, 27], and is often
elevated in patients with NASH [1, 27]. The CWF19L1 gene is conserved in several species;
however its function remains unknown.
The SCD gene (10q24.31), located 79 kb downstream from the 5′utr-CWF19L1-
rs12784396, was previously reported influence NAFLD in mice and in humans. SCD
encodes the stearoyl-CoA desaturase 1 (SCD1) and is involved in both the lipogenic as well
as the lipid oxidative pathways [28]. SCD1 is a central enzyme in lipid metabolism; it
converts saturated fatty acids to monounsaturated fatty acids, which are major substrates for
synthesis of triacylglycerols and other lipids [28]. SCD1 knockout mice were resistant to the
development of obesity and hepatic steatosis [28], whereas the activity of SCD1 was
significantly increased in the fatty livers of ob/ob mice. In addition, hepatic SCD1 activity
was increased in nonalcoholic human fatty liver [29], and associated with fatty liver and
insulin resistance in obese humans [30]. Although SCD is a plausible candidate gene for
NAFLD, we could not detect association of variants within the SCD gene with NAFLD
traits (FL and ALT) nor has any other study found such an association, as far as we know.
However, as it was previously suggested in mice, the activation of the transcription of SCD1
may occur via the numerous NF-B elements in the SCD1 promoter [28], and/or occur via
endoplasmic reticulum stress and inflammatory response mRNAs [31]. If there is a pathway
linking activity of SCD1 and CHUK protein-inhibitor NF-κB, and/or activity of SCD1 and
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ERLIN-1 protein of lipid-raft-like domain are unknown, and further studies will be
necessary to prove or disprove these hypotheses in human.
Presently, it is not possible to accurately predict which subjects with simple steatosis will
develop to steatohepatitis and fibrosis, and much less is known about genetic variants
influencing the progression of NAFLD. These findings suggest that variants within the
ERLIN1-CHUK-CWF19L1 gene cluster contribute to the increased susceptibility to simple
steatosis (current FamHS results), hepatic injury (ALT [8], and the current FamHS results)
and NAFLD histological severity (fibrosis [13]). It could be plausible that the evolution of
NAFLD, from simple steatosis to hepatic inflammation to fibrosis, is due to the critical
accumulation of liver fat, and they do not represent separate effects. Further studies will be
necessary to understand the diagnosis and progression of NAFLD. Furthermore, our meta-
analysis approach is the first study to report a correlated association between ERLIN1-
CHUK-CWF19L1 variants with the liver fat content and serum plasma ALT levels.
Although our study shows evidence that variants of this gene cluster confer increased
susceptibility to a broad spectrum of NAFLD, additional investigations will be necessary to
understand how genetic effects of ERLIN1-CHUK-CWF19L1 contribute to individual
susceptibility to simple steatosis to the development of hepatic inflammation.
Our study has some limitations but several relevant strengths. Some of the strengths include:
ALT levels are known as a sensitive screening test in detecting liver disease better than AST
(aspartate aminotransferase) or other biochemical markers [32], and are strongly correlated
with biopsy-proven fatty liver disease [6]. ALT levels have also been used to define NAFLD
in epidemiological studies. Fatty liver accumulation was directly measured by CT liver
attenuation, which is a non-invasive procedure that provides an accurate characterization of
fat burden [3, 4]. Our novel correlated meta-analysis approach also provided an objective
method to screen variants influencing correlated phenotypes, which resulted in associations
that implicate novel variants (e.g., rs12784396 in the utr-5 CWF19L1) for NAFLD. Also,
some SNPs that we found associations with concomitant variations of FL and ALT were
previously reported associations with ALT levels [8] and with histological fibrosis [13]. The
evidence of association between missense-ERLIN1-rs2862954 with NAFLD traits warrant
functional followup studies. A limitation of our study is that ALT levels and CT measured
FL do not provide the clinical precision of diagnostic forms of liver disease based on
histology, which would require biopsies. However, we excluded subjects with high alcohol
intake and hepatitis C positive to reduce this possible source of heterogeneity. Moreover,
both CT measured FL and ALT levels bring opportunity to study NAFLD.
In brief, our study identified common variants of the ERLIN1-CHUK-CWF19L1 gene
cluster associated with NAFLD in a wide spectrum, simple steatosis, as CT measured FL,
and hepatic inflammation measured by plasma levels of ALT. The discovery of these
genetic variants may aid in understanding the correlated architecture between liver fat
deposition and inflammation process, NAFLD development, and the prospective risk factors
including type 2 diabetes and cardiovascular disease.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Sources of Funding
This study was supported by the by NIH grants R01-HL-087700 and R01-HL-088215 (Michael A. Province, PI)
from NHLBI; and R01-DK-8925601 and R01-DK-075681 (Ingrid B. Borecki, PI) from NIDDK.
Feitosa et al. Page 7














1. Lewis JR, Mohanty SR. Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci. 2010;
55:560–578. [PubMed: 20101463]
2. Musso G, Gambino R, Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic
fatty liver disease (NAFLD). Prog Lipid Res. 2009; 48:1–26. [PubMed: 18824034]
3. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment
and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J
Hepatol. 2009; 51:433–445. [PubMed: 19604596]
4. Boyce CJ, Pickhardt PJ, Kim DH, et al. Hepatic steatosis (fatty liver disease) in asymptomatic adults
identified by unenhanced low-dose CT. AJR Am J Roentgenol. 2010; 194:623–628. [PubMed:
20173137]
5. Yamada J, Tomiyama H, Yambe M, et al. Elevated serum levels of alanine aminotransferase and
gamma glutamyltransferase are markers of inflammation and oxidative stress independent of the
metabolic syndrome. Atherosclerosis. 2006; 189:198–205. [PubMed: 16405892]
6. Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ. Alanine
aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes
mellitus and cardiovascular disease. Diabetes Metab Res Rev. 2006; 22:437–443. [PubMed:
16832839]
7. Speliotes EK, Yerges-Armstrong LM, Wu J, et al. Genomewide association analysis identifies
variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits.
PLoS Genet. 2011; 7:e1001324. [PubMed: 21423719]
8. Yuan X, Waterworth D, Perry JR, et al. Population-based genomewide association studies reveal six
loci influencing plasma levels of liver enzymes. Am J Hum Genet. 2008; 83:520–528. [PubMed:
18940312]
9. Makkonen J, Pietiläinen KH, Rissanen A, Kaprio J, Yki-Järvinen H. Genetic factors contribute to
variation in serum alanine aminotransferase activity independent of obesity and alcohol: a study in
monozygotic and dizygotic twins. J Hepatol. 2009; 50:1035–1042. [PubMed: 19303161]
10. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to
nonalcoholic fatty liver disease. Nat Genet. 2008; 40:1461–1465. [PubMed: 18820647]
11. Kotronen A, Johansson LE, Johansson LM, et al. A common variant in PNPLA3, which encodes
adiponutrin, is associated with liver fat content in humans. Diabetologia. 2009; 52:1056–60.
[PubMed: 19224197]
12. Sookoian S, Castaño GO, Burgueño AL, Gianotti TF, Rosselli MS, Pirola CJ. A nonsynonymous
gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J
Lipid Res. 2009; 50:2111–2116. [PubMed: 19738004]
13. Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ, NASH CRN. The association of genetic
variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological
severity of nonalcoholic fatty liver disease. Hepatology. 2010; 52:894–903. [PubMed: 20684021]
14. Devries MC, Samjoo IA, Hamadeh MJ, Tarnopolsky MA. Effect of endurance exercise on hepatic
lipid content, enzymes, and adiposity in men and women. Obesity (Silver Spring). 2008; 16:2281–
2288. [PubMed: 18719669]
15. Higgins M, Province M, Heiss G, et al. NHLBI Family Heart Study: objectives and design. Am J
Epidemiol. 1996; 143:1219–1228. [PubMed: 8651220]
16. Carr JJ, Nelson JC, Wong ND, et al. Calcified coronary artery plaque measurement with cardiac
CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis
(MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study. Radiology.
2005; 234:35–43. [PubMed: 15618373]
17. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ. 2005;
172:367–379. [PubMed: 15684121]
18. Kraja AT, Vaidya D, Pankow JS, et al. A bivariate genomewide approach to metabolic syndrome:
STAMPEED consortium. Diabetes. 2011; 60:1329–1339. [PubMed: 21386085]
Feitosa et al. Page 8













19. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components
analysis corrects for stratification in genomewide association studies. Nat Genet. 2006; 38:904–
909. [PubMed: 16862161]
20. Province, MA.; Borecki, IB. A correlated meta-analysis strategy for data mining “OMIC” scans.
PSB 2013 Online Proceedings; (on press: http://psb.stanford.edu/psb-online/proceedings/psb13/)
21. Borecki IB, Province MA. Genetic and genomic discovery using family studies. Circulation. 2008;
118:1057–1063. [PubMed: 18765388]
22. Pruim RJ, Welch RP, Sanna S, et al. LocusZoom: regional visualization of genomewide
association scan results. Bioinformatics. 2010; 26:2336–2337. [PubMed: 20634204]
23. Browman DT, Resek ME, Zajchowski LD, Robbins SM. Erlin-1 and erlin-2 are novel members of
the prohibitin family of proteins that define lipid-raft-like domains of the ER. J Cell Sci. 2006;
119:3149–3160. [PubMed: 16835267]
24. Calder PC, Yaqoob P. Lipid rafts--composition, characterization, and controversies. J Nutr. 2007;
137:545–547. [PubMed: 17311937]
25. Li N, Huang X, Zhao Z, Chen G, Zhang W, Cao X. Identification and characterization of a novel
gene KE04 differentially expressed by activated human dendritic cells. Biochem Biophys Res
Commun. 2000; 279:487–493. [PubMed: 11118313]
26. Nseir W, Shalata A, Marmor A, Assy N. Mechanisms Linking Nonalcoholic Fatty Liver Disease
with Coronary Artery Disease. Dig Dis Sci. 2011; 56:3439–3449. [PubMed: 21655948]
27. Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L. Molecular mechanisms involved in
NAFLD progression. J Mol Med. 2009; 87:679–695. [PubMed: 19352614]
28. Flowers MT, Ntambi JM. Role of stearoyl-coenzyme A desaturase in regulating lipid metabolism.
Curr Opin Lipidol. 2008; 19:248–256. [PubMed: 18460915]
29. Kotronen A, Seppänen-Laakso T, Westerbacka J, et al. Hepatic stearoyl-CoA desaturase (SCD)-1
activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic
human fatty liver. Diabetes. 2009; 58:203–208. [PubMed: 18952834]
30. Stefan N, Peter A, Cegan A, et al. Low hepatic stearoyl-CoA desaturase 1 activity is associated
with fatty liver and insulin resistance in obese humans. Diabetologia. 2008; 51:648–656.
[PubMed: 18286258]
31. Flowers MT, Keller MP, Choi Y, et al. Liver gene expression analysis reveals endoplasmic
reticulum stress and metabolic dysfunction in SCD1-deficient mice fed a very low-fat diet. Physiol
Genomics. 2008; 33:361–372. [PubMed: 18381840]
32. Ciba I, Widhalm K. The association between non-alcoholic fatty liver disease and insulin
resistance in 20 obese children and adolescents. Acta Paediatr. 2007; 96:109–112. [PubMed:
17187615]
Feitosa et al. Page 9














We employed a novel correlated meta-analysis to improve the power to detect
variants associated with NAFLD.
NAFLD was assessed by using CT measured fatty liver and alanine aminotransferase
levels (ALT).
Correlated meta-analysis allowed to identify variants of the ERLIN1-CHUK-
CWF19L1 associated with CT measured fatty liver and ALT levels.
Variants of the ERLIN1-CHUK-CWF19L1 are associated with the joint effect of
steatosis (FL ≥ 40 HU) and inflammation (ALT ≥40 U/L).
Variants of the ERLIN1-CHUK-CWF19L1 gene cluster may aid in understanding
the correlated architecture between liver fat deposition and inflammation process.
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Regional plot of ERLIN1-CHUK-CWF19L1 gene cluster based on FamHS imputed
genotype data. The CMA – log P value for correlated FL and ALT pair is represented in the
ordinate axis, while the chromosome 10 position in Megabase (Mb) using build 35 is
represented in the abscissa axis. The bottom panels give the relative positions of genes in the
locus. Purple diamond indicates the effect of rs10883451 with the correlated FL and ALT
pair. Each circle indicates a SNP with the color of the circle representing the correlation (r2)
between that SNP and rs10883451. Blue line indicates estimated recombination hotspots in
HapMap.
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Table 1
Characteristics of phenotypes in the FamHS
Number Mean ± SD Minimum Maximum
Sample (% of females) 2,705 (55%)
Age (years) 2,705 57.1 ± 13.3 30.0 93.0
Alcohol intake (drinks/week) 2,705 3.0 ± 7.1 0 171
CT liver attenuation (HU) 2,597 59.28 ± 11.02 −5.8 88.6
ALT (U/L) 2,584 21.1 ± 13.3 4.0 241.0
Triglycerides (mg/dL) 2,654 144.1 ± 93.9 24.0 1,037.0
Waist circumference (cm) 2,705 98.8 ± 16.3 58.0 187.0
Body mass index (kg/m2) 2,705 28.9 ± 5.7 14.4 57.6
Severe obesity (NTotal; % of affected) 338 (2,705; 12.5%)
HOMA-IR 2,613 2.8 ± 2. 9 0.3 66.4
Diabetes (NTotal; % of affected) 362 (2,705; 13.4%)
HOMA-IR: Homeostatic Model Assessment (fasting glucose (mmol/L)*fasting insulin (mU/L)/22.5);
Diabetes: taking hyperglycemic medication and/or fasting glucose ≥ 126 ml/dl;
Severe obesity: BMI ≥ 35.0 kg/m2
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